<DOC>
	<DOCNO>NCT02236702</DOCNO>
	<brief_summary>The purpose study use positron emission tomography ( PET ) image measure activity kappa opioid receptor ( KOR ) brain depressed non-depressed individual .</brief_summary>
	<brief_title>Kappa Opioid Receptor Imaging Depression ( KOR Depression )</brief_title>
	<detailed_description>The kappa opioid receptor ( KOR ) implicate etiology fear , threat , anhedonia animal model human depression psychopathology . Herein , propose study KOR vivo use positron emission tomography , also measure activity hypothalamic-pituitary-adrenal ( HPA ) -axis study participant . We propose recruit N=50 medication-free individual use transdiagnostic approach , measure KOR-selective radioligand [ 11C ] LY2795050 volume distribution ( VT ) , equivalent KOR availability use positron emission tomography ( PET ) study role KOR mediate quality severity depressive phenotype .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Anhedonia</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>1 . Inclusion criterion subject include willingness participate psychiatric evaluation , collection behavioral rating neuroendocrine assessment , image study include 1 positron emission tomography ( PET ) scan 1 mantic resonance imaging ( MRI ) scan . 2 . We propose use transdiagnostic approach participant stratify accord symptom severity full representation different depressive severity component depressive phenotype cohort . To ensure recruitment participant level phenotype , employ stratify sample approach recruit 12 participant asymptomatic ( i.e. , MontgomeryAsberg Depression Rating Scale ( MADRS ) score=06 ) ; 12 mildly symptomatic ( i.e. , MADRS score=719 ; 12 moderately symptomatic ( i.e. , MADRS sore=2034 ) ; 12 severely symptomatic ( i.e. , MADRS score &gt; 34 ) . 1. major medical ( include HIV due possible neuropsychiatric affect ; asthma heart disease may limit interpretation image result , example due change tracer delivery hypertensive patient significant weight change prior 12 week prior study ) neurological illness injury ( i.e . head trauma loss consciousness ) ; 2. current prior clinically significant substance use disorder ( abuse dependence within year image study ) determine Structured Clinical Interview Diagnostic Statistical Manual Disorders ( SCID ) interview ; 3. acute chronic suicidality determine SCID interview ; 4. presence legal illegal psychoactive substance determine urine toxicology , urine cotinine , carbon monoxide ( CO ) monitoring , breathalyzer ; 5. intelligence quotient ( IQ ) &lt; 70 base past intelligence testing ; 6. metal body would pose risk MRI ; 7. claustrophobia would interfere MRI PET imaging ; 8. pregnancy nursing woman ; 9. woman estrogen and/or progesterone level outside normal range , birth control pill , peri post menopausal woman , ovarectomies ; 10. obesity define body mass index ( BMI ) &gt; 35 ; 11. use psychoactive medication include regular use benzodiazepine ; 12. abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participation study ; 13. lifetime history use abuse opioids ; 14. presence psychotic symptom patient mood anxiety disorder , schizophrenia schizoaffective disorder ; 15. blood donation within 8 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Anhedonia</keyword>
	<keyword>Positron Emission Tomography ( PET )</keyword>
	<keyword>Kappa Opioid Receptor ( KOR )</keyword>
</DOC>